HomeAI · summaries
Storia in 20 fonti
mRNA’s second act: A bespoke cancer vaccine & what Merck-Moderna’s melanoma trial could mean for oncology
The Phase 3 INTerpath-001 trial delivered oncology's first personalised cancer vaccine win, and mRNA a therapeutic breakthrough since the pandemic.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
en.mercopress.com
A personalized mRNA therapy passes a phase 3 melanoma trial for the first time
Pharmaceutical companies Merck, known as MSD outside the United States and Canada, and Moderna announced on Wednesday that their individualized neoantigen therapy, intismeran…
- ·
biopharmadive.com
Moderna and Merck cancer vaccine returns ‘landmark’ result in melanoma
At an interim data check, investigators of a key trial found the individualized mRNA treatment kept disease from returning and stopped its spread, sparking a surge in Moderna…
